Alprostadil Articles
Profit drop for Taisho, but firm sees recovery
5 June 2009
Vivus' 3rd-qtr profit drops 79% on R&D costs
17 November 2008
Vivus signs $30M to fund ED drug trials
14 April 2008
Vivus posts $10M 4th-qtr 2007 profit
24 March 2008
Vivus' 2nd-qtr loss grows 16% on Qnexa costs
13 August 2007
Vivus' 1st-qtr 2007 net loss narrows to $7.4M
21 May 2007
Headlines 25 years ago this week....
29 January 2007
Stock Commentary - New York week to Nov 6, 2006
13 November 2006
Stock Commentary - New York week to Oct 9, 2006
16 October 2006
Stock Commentary - New York week to Aug 7, 2006
7 August 2006
Japan stock market week to Nov 28
5 December 2005
Stock Commentary - New York
20 June 2005
Vivus initiates Ph II Alista trial
20 September 2004
Stock Commentary - New York
26 July 2004
Net loss higher at Vivus in 2nd qtr
26 July 2004
Positive Ph II data for Vivus' Alista
19 July 2004
NexMed and Schering AG sign deal for Alprox-TD
12 July 2004
MacroChem's Topiglan disappoints in Ph II
26 April 2004
Global peripheral neuropathy market worth $1B by 2012
19 April 2004
CJ Corp and NexMed in FemProx marketing deal
29 March 2004
NexMed licenses Femprox out in South Korea
23 February 2004
Stock Commentary - New York
5 January 2004
VIVUS' Muse reimbursed in Sweden
9 June 2003
Vivus makes $17.5M plalcing
2 June 2003
Stock Commentary - New York
7 April 2003
Vivus recruiting for Ph II Alista trial
24 March 2003
NexMed raises $5M from note and warrants issue
24 June 2002
NexMed's Befar launched in Hong Kong
29 April 2002
MUSE sales on the up at Vivus
25 March 2002
NexMed files for topical impotence drug in Singapore
28 November 2001
VIVUS pulls Alibra application in Europe
22 November 2001
Alprostadil likely to gain new ED patients
9 October 2001
NexMed plans pivotal trials of ED drug
21 September 2001
MacroChem's Topiglan for ED clears Ph III trial
6 September 2001
Vivus completes Ph II dosing of Alista
24 August 2001
NexMed's Alprox effective for ED in Phase II
7 June 2001
Vivus licenses MED drug from Tanabe
8 March 2001
VIVUS starts Ph II Alista trials
25 January 2001
Vivus' Actis cleared for OTC use
2 January 2001
Chinese approval for NexMed's Alprox-TD?
13 December 2000
Vaccines acquisition set to drive near-term growth at PowderJect
12 December 2000
Vivus signs Paladin for Muse in Canada
23 November 2000
Topical impotence drug making progress
6 November 2000
Vivus falls on withdrawal of Alibra NDA for impotence
24 October 2000
Vivus signs ED deal with Abbott
21 June 2000
VIVUS files for EU approval of Alibra
1 June 2000
AstraZeneca/Vivus alprostadil distribution deal resolved
5 January 2000
Vivus shares double on ALIBRA filing, new impotence drug
23 December 1999
PowderJect has strong fundamentals, says broker
10 December 1999
State of development in Ono Pharma R&D pipeline
10 November 1999
AstraZeneca pulls out of Muse deal
11 October 1999
P&U patient info on Caverject
14 September 1999
Vivus terminates Bio-Medic deal
15 July 1999
Vivus signs $5 mill deal for MUSE in Japan
18 May 1999
-Vivus' MUSE (alprostadil) approved in France
29 March 1999
-Vivus granted approval to launch Muse in Germany
4 March 1999
Bioject - one step ahead in a needle-free world
10 February 1999
PowderJect DNA Hep B Vaccine Is Immunogenic
8 December 1998
Nexmed's Befar Safe In Phase III
3 December 1998
Latest Wave Of US 1st Quarter Results
29 October 1998
Japan's Ono Pharma Highlights R&D Pipeline
28 October 1998
ED: Better Communication & Education Still Needed
24 September 1998
Vivus' MUSE Approvals
20 August 1998
First Approval For Senetek's Invicorp
14 July 1998
Vivus Stock Rising To Impotence Challenge
9 July 1998
Copromotion For MUSE In USA
9 July 1998
Viagra Still Riding High, But Competition Looms
15 June 1998
Sound Platform Set Up At PowderJect
15 June 1998
Pfizer's Viagra Already Has 95% Share Of ED Market
30 April 1998
Astra's Bondil OKed In Sweden
23 April 1998
PowderJect's Needlefree Alprostadil
22 April 1998
Unprecedented Take-Off For Pfizer's Viagra
21 April 1998
Demand For Vivus' MUSE Remains Flat
15 April 1998
Vivus To Triple Its Sales Force
1 April 1998
Pfizer's Impotence Pill Wins FDA Clearance
31 March 1998
Senetek's Invicorp "70% Effective"
12 March 1998
MacroChem's Topiglan: Phase IIb Data
5 March 1998
UK Launch Of Astra's MUSE
17 February 1998
Irish Investment Plan For VIVUS
21 January 1998
R&D Spending Up 300% At Powderject
11 December 1997
1st Non-US Approval For VIVUS' MUSE
4 December 1997
VIVUS And Janssen Sign Second Marketing Agreement For MUSE
6 November 1997
Fournier's Erecnos Boosted By Clinical Trial Results
8 October 1997
Topical Impotence Drug Promising
26 June 1997
Supersonic Drug Delivery Firm Seeks UK Listing
26 May 1997
VIVUS' MUSE "Effective After Prostatectomy"
5 May 1997
Vivus' EPS Is Higher Than Expectations
21 April 1997
Vivus Shares Tumble On MUSE Concerns
3 March 1997
VIVUS Signs MUSE Marketing Deal With Janssen Pharmaceutica
3 February 1997
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
